A comparison of point and ball iterations in the contractive mapping case

Zongben Xu,X. Shi

DOI: https://doi.org/10.1007/BF02238651

1993-01-02

Computing

Abstract:

What problem does this paper attempt to address?

Analysis and Optimal Design of Batch and Two‐column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Ce Shi,Sebastian Vogg,Dong-Qiang Lin,Mattia Sponchioni,Massimo Morbidelli

DOI: https://doi.org/10.1002/bit.27763

IF: 3.8

2021-01-01

Biotechnology and Bioengineering

Abstract:The increasing demand for efficient and robust processes in the purification of monoclonal antibodies (mAbs) has recently brought frontal chromatography to the forefront. Applied during the polishing step, it enables the removal of high molecular weight aggregates from the target product, achieving high purities. Typically, this process is operated in batch using a single column, which makes it intrinsically subjected to a purity-yield tradeoff. This means that high purities can only be achieved at the cost of lowering the product yield and vice versa. Recently, a two-column continuous implementation of frontal chromatography, referred to as Flow2, was developed. Despite being able of alleviating the purity-yield tradeoff typical of batch operations, the increase in the number of process parameters complicates its optimal design, with the risk of not exploiting its full potential. In this study, we developed an ad hoc design procedure (DP) suitable for the optimization of both batch frontal chromatography and Flow2 in terms of purity, yield, and productivity. This procedure provided similar results as a multiobjective optimization based on genetic algorithm but with lower computational effort. Then, batch and Flow2 operated at their optimal conditions were compared. Besides showing a more favorable Pareto front of yield and productivity at a specified purity, the Flow2 process demonstrated improved robustness compared to the batch process with respect to modifications in the loading linear velocity, washing buffer ionic strength and loading time, thus providing an appealing operation for integrated processes.
Analysis and Optimal Design of Batch and Two-Column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Ce Shi,Sebastian Vogg,Dong-Qiang Lin,Mattia Sponchioni,Massimo Morbidelli

DOI: https://doi.org/10.22541/au.160759315.56793972/v1

2020-01-01

Abstract:Frontal chromatography has seen increased interest for protein purification, in particular as a polishing step in downstream processes for therapeutic proteins production, as for example the purification of monoclonal antibodies (mAbs) from high molecular weight impurities, e.g., aggregates, using cation exchange resins. In this work we introduce a new two-column continuous process implementing frontal chromatography. The design procedure and its performance, compared to classical batch technology, are discussed. This represents an additional option in the realisation of optimised continuous downstream processing of therapeutic proteins.
68Ga-labeled macroaggregates for lung studies.

L. Colombetti,D. Goodwin,E. Togami

1970-12-01

Journal of Nuclear Medicine

Abstract:
A case study application of AQbD to the re-development and validation of an affinity chromatography analytical procedure for mAb titer quantitation

Terezie Cernosek,Matthew Dalphin,Nitin Jain,Jason Lor,Noah Richter,Mourad Mellal,Sue Behrens,Peter Wunderli

DOI: https://doi.org/10.1016/j.jchromb.2024.124205

2024-07-15

Abstract:Protein A (ProA) high-performance liquid chromatography (HPLC) is a common analytical procedure for measuring monoclonal antibody (mAb) titers due to its high specificity and efficiency. Accurate and reliable results of this procedure are imperative, as the quantitation of the total mAb present for in-process samples directly impacts downstream purification steps related to the removal of process-related impurities. This study aimed to improve a platform ProA HPLC analytical procedure which was previously developed using traditional approaches and was not always reliable. By retrospectively applying Analytical Quality by Design (AQbD) principles and statistical assessments of performance, a bias in the calibration standard due to protein-adsorption to common sample vial materials was identified. The inclusion of Tween® 20 into the mobile phase used as sample diluent was optimized to ensure procedure performance and improve analytical range. The resulting procedure robustness was evaluated using Design of Experiment (DoE) approaches and performance was verified against Analytical Target Profile (ATP) criteria as recommended by regulatory agencies. The resulting linearity displayed R2 values of 1.00 with intercept biases of 1.2 % (analyst 1) and 0.8 % (analyst 2), accuracy across all levels was reported at 99.2 % recovery, and intermediate precision was reported as 3.0 % RSD. Application of this new platform procedure has since reduced development timelines for new mAb products by 50 % and allowed for accurate titer determination to support >5 early phase product-specific process decisions without requiring extensive analytical procedure development. This work demonstrates the utility and relative ease of adopting AQbD concepts, even for established procedures, and supporting them with a lifecycle approach to managing procedure performance.
[To further improve the techniques for repair and reconstruction of skin and soft tissue defects around the knee joints].

Xiao-Yuan Huang

DOI: https://doi.org/10.3760/CMA.J.ISSN.1009-2587.2015.05.002

2015-10-01

Abstract:This article briefly summarizes the techniques for repair of skin and soft tissue defects around the knee joints as reported in 5 papers in this issue, including how to choose the skin flap, muscle flap, myocutaneous flap, and vascular anastomosis in recipient site. It is found that the anterolateral femoral flap, latissimus dorsi myocutaneous flap, and gastrocnemius flap are widely used in clinic with high survival rates, and they can be used for the repair of large soft tissue defects as well as the reconstruction of the knee joint function.
Establishment and validation of a microfluidic capillary gel electrophoresis platform method for purity analysis of therapeutic monoclonal antibodies

Michael T Smith,Shu Zhang,Troy Adams,Byron DiPaolo,Jennifer Dally

DOI: https://doi.org/10.1002/elps.201600519

Electrophoresis

Abstract:Capillary and microfluidic chip electrophoresis technologies are heavily utilized for development, characterization, release, and stability testing of biopharmaceuticals. Within the biopharmaceutical industry, CE-SDS and M-CGE are commonly used for purity determination by separation and quantitation of size-based variants. M-CGE is used primarily as an R&D tool for product and process development, while cGMP release and stability testing applications are commonly reserved for CE-SDS. This paper describes the establishment of an M-CGE platform method to be used for R&D and cGMP applications, including release and stability testing, for monoclonal antibodies. The M-CGE platform method enables testing for product development support and cGMP release and stability using the same method, and utilization of one CE technology for the entire lifecycle of a biopharmaceutical product. Critical method parameters were identified, and the analytical design space of those critical parameters was defined using design of experiments (DOE) studies. Once defined through DOE studies, the method design space was validated according to ICH Q2 (R1) guidelines. Additional molecules of the same validated class were verified for use in the method by experimental confirmation of accuracy, specificity, and stability indicating capabilities. The platform method model facilitates rapid utilization of the method in development and GMP testing environments, and eliminates the need for individual validations for assets of the same class entering early stage development.
Quality by Design Study of the Direct Analysis in Real Time Mass Spectrometry Response

Lu Wang,Teng Chen,Shanshan Zeng,Haibin Qu

DOI: https://doi.org/10.1007/s13361-013-0779-6

IF: 3.262

2013-01-01

Journal of the American Society for Mass Spectrometry

Abstract:A mass spectrometry method has been developed using the Quality by Design (QbD) principle. Direct analysis in real time mass spectrometry (DART-MS) was adopted to analyze a pharmaceutical preparation. A fishbone diagram for DART-MS and the Plackett-Burman design were utilized to evaluate the impact of a number of factors on the method performance. Multivariate regression and Pareto ranking analysis indicated that the temperature, determined distance, and sampler speed were statistically significant (P < 0.05). Furthermore, the Box-Behnken design combined with response surface analysis was then employed to study the relationships between these three factors and the quality of the DART-MS analysis. The analytical design space of DART-MS was thus constructed and its robustness was validated. In this presented approach, method performance was mathematically described as a composite desirability function of the critical quality attributes (CQAs). Two terms of method validation, including analytical repeatability and method robustness, were carried out at an operating work point. Finally, the validated method was successfully applied to the pharmaceutical quality assurance in different manufacturing batches. These results revealed that the QbD concept was practical in DART-MS method development. Meanwhile, the determined quality was controlled by the analytical design space. This presented strategy provided a tutorial to the development of a robust QbD-compliant mass spectrometry method for industrial quality control.
Accelerated development of a SEC-HPLC procedure for purity analysis of monoclonal antibodies using design of experiments

Terezie Cernosek,Nitin Jain,Matthew Dalphin,Sue Behrens,Peter Wunderli

DOI: https://doi.org/10.1016/j.jchromb.2024.124037

2024-03-01

Abstract:The complex structure of biopharmaceutical products poses an inherent need for their thorough characterization to ensure product quality, safety, and efficacy. Analytical size exclusion chromatography (SEC) is a widely used technique throughout the development and manufacturing of monoclonal antibodies (mAbs) which quantifies product size variants such as aggregates and fragments. Aggregate and fragment content are critical quality attributes (CQAs) in mAb products, as higher contents of such size heterogeneities impact product quality. Historically, SEC methods have achieved sufficient separation between the high molecular weight (HMW) species and the main product. In contrast, some low molecular weight (LMW) species are often not sufficiently different in molecular mass from the main product, making it difficult to achieve appropriate resolutions between the two species. This lack of resolution makes it difficult to consistently quantify the LMW species in mAb-based therapeutics. The following work uses a design of experiments (DoE) approach to establish a robust analytical SEC procedure by evaluating SEC column types and mobile phase compositions using two mAb products with different physiochemical properties. The resulting optimized procedure using a Waters™ BioResolve column exhibits an improved ability to resolve and quantify mAb size variants, highlighting improvement in the resolution of the LMW species. Additionally, the addition of L-arginine as a mobile phase additive showed to reduce secondary interactions and was beneficial in increasing the recoveries of the HMW species.
Seizures at the scale of individual neurons.

Eyal Y. Kimchi,S. Cash

DOI: https://doi.org/10.1093/brain/awv264

2015-10-01

Abstract:This scientific commentary refers to ‘Single unit action potentials in humans and the effect of seizure activity’ by Merricks et al. (doi:10.1093/brain/awv208). Seizures are commonly accepted to be events characterized by brief periods of abnormal neuronal firing. However, the basic physiology of what occurs during a seizure remains poorly understood. This significant shortfall prevents us from developing new treatments for the one-third of patients with epilepsy who do not obtain substantial control of their seizures with maximal medical therapy. Beginning in the 1950s, researchers began to address the physiology gap with recordings in models of seizures, including recordings of neural activity in small numbers of individual neurons. First in animal models and now more recently in human patients, studies of individual neurons have described how neural activity changes as seizures start, spread and terminate. These studies, however, have also fuelled additional questions about how seizures can be defined, characterized and ultimately brought under control. The canonical view of a typical seizure is that it represents excessive or ‘hypersynchronous’ activity in a large group of neurons. This textbook model is a satisfactory shorthand for the overall process of a seizure, but neglects noteworthy heterogeneity and important unknowns. In the last decade or so, work from many groups using a …
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring

Adam R. Evans,Joseph Mulholland,Michael J. Lewis,Ping Hu

DOI: https://doi.org/10.1080/19420862.2024.2341641

2024-04-24

mAbs

Abstract:Peptide mapping with mass spectrometry (MS) is an important tool for protein characterization in the biopharmaceutical industry. Historically, peptide mapping monitors post-translational modifications (PTMs) of protein products and process intermediates during development. Multi-attribute monitoring (MAM) methods have been used previously in commercial release and stability testing panels to ensure control of selected critical quality attributes (CQAs). Our goal is to use MAM methods as part of an overall analytical testing strategy specifically focused on CQAs, while removing or replacing historical separation methods that do not effectively distinguish CQAs from non-CQAs due to co-elution. For example, in this study, we developed a strategy to replace a profile-based ion-exchange chromatography (IEC) method using a MAM method in combination with traditional purity methods to ensure control of charge variant CQAs for a commercial antibody (mAb) drug product (DP). To support this change in commercial testing strategy, the charge variant CQAs were identified and characterized during development by high-resolution LC-MS and LC-MS/MS. The charge variant CQAs included PTMs, high molecular weight species, and low molecular weight species. Thus, removal of the IEC method from the DP specification was achieved using a validated LC-MS MAM method on a QDa system to directly measure the charge variant PTM CQAs in combination with size exclusion chromatography (SE-HPLC) and capillary electrophoresis (CE-SDS) to measure the non-PTM charge variant CQAs. Bridging data between the MAM, IEC, and SE-HPLC methods were included in the commercial marketing application to justify removing IEC from the DP specification. We have also used this MAM method as a test for identity to reduce the number of QC assays. This strategy has received approvals from several health authorities.

medicine, research & experimental
Determination of size variants by CE-SDS for approved therapeutic antibodies: Key implications of subclasses and light chain specificities

Elsa Wagner,Olivier Colas,Stéphane Chenu,Alexandre Goyon,Amarande Murisier,Sarah Cianferani,Yannis François,Szabolcs Fekete,Davy Guillarme,Valentina D'Atri,Alain Beck

DOI: https://doi.org/10.1016/j.jpba.2020.113166

2020-05-30

Abstract:In the present work, a generic non-reducing capillary electrophoresis sodium dodecyl sulphate (nrCE-SDS) method was tested for a wide range of 26 FDA and EMA approved monoclonal antibodies (mAbs) and 2 antibody drug conjugates (ADCs) as well as for the NISTmab, in a QC environment (e.g. testing quality requirements for batch manufacturing or batch release). This method allows obtaining rapidly and accurately the amount of size variants in drug products within about 40 min and may be used for batch release and consistency as well as for stability and shelf-life. First, the method repeatability was found to be excellent in terms of relative migration times and relative proportions of fragments (average RSD values of 0.3 and 0.2 %, on relative migration times and relative percentages of fragments, respectively), thanks to the addition of an internal standard. A panel of chimeric, humanized and human mAbs were tested, belonging to different subclasses (heavy chain gamma 1, 2, 2/4 and 4) and light chain types (κ or λ) and produced in different cell lines (CHO, NS0 and SP2/0). For all these biopharmaceutical products, the amount of H2L2 species was comprised between 90.9 % and 97.7 %, except for the two mAbs belonging to the IgG1λ subclass, namely avelumab and belimumab, which were prone to partial reduction during the sample preparation at 70 °C. Based on the CE-SDS results obtained for a diverse panel of therapeutic antibodies investigated in this study, and covering a wide range of structural and physico-chemical properties, a specification on the intact antibody content (H2L2) greater than 90 % can be achieved.
Delivery of primary care services among family planning centers: a response to managed care?

V. Poole,C. Weisman

DOI: https://doi.org/10.1016/S1049-3867(00)00059-1

2000-11-01

Abstract:
Improved CE(SDS)-CZE-MS method utilizing an 8-port nanoliter valve

Jennifer Römer,Steffen Kiessig,Bernd Moritz,Christian Neusüß

DOI: https://doi.org/10.1002/elps.202000180

Electrophoresis

Abstract:Capillary sieving electrophoresis utilizing SDS (CE(SDS)) is one of the most applied methods for the analysis of antibody (mAb) size heterogeneity in the biopharmaceutical industry. Inadequate peak identification of observed protein fragments is still a major issue. In a recent publication, we introduced an electrophoretic 2D system, enabling online mass spectrometric detection of generic CE(SDS) separated peaks and identification of several mAb fragments. However, an improvement regarding system stability and handling of the approach was desired. Here, we introduce a novel 8-port valve in conjunction with an optimized decomplexation strategy. The valve contains four sample loops with increased distances between the separation dimensions. Thus, successively coinjection of solvent and cationic surfactant without any additional detector in the second dimension is enabled, simplifying the decomplexation strategy. Removal efficiency was optimized by testing different volumes of solvents as presample and cationic surfactant as postsample zone. 2D measurements of the light and heavy chain of the reduced NIST mAb with the 8-port valve and the optimized decomplexation strategy demonstrates the increased robustness of the system. The presented novel set-up is a step toward routine application of CE(SDS)-CZE-MS for impurity characterization of proteins in the biopharmaceutical field.
Capillary electrophoresis and the biopharmaceutical industry: Therapeutic protein analysis and characterization

Harleen Kaur,Jeff Beckman,Yiting Zhang,Zheng Jian Li,Marton Szigeti,Andras Guttman

DOI: https://doi.org/10.1016/j.trac.2021.116407

IF: 14.908

2021-11-01

TrAC Trends in Analytical Chemistry

Abstract:Capillary electrophoresis (CE) has emerged as a powerful technique for comprehensive physicochemical characterization of monoclonal antibodies (mAbs) as well as other therapeutic modalities. The method provides high resolution separation and high sensitivity characterization for analysis of therapeutic biomolecules. CE based techniques such as sodium dodecyl sulphate capillary gel electrophoresis (SDS-CGE, also referred to as CE SDS), capillary zone electrophoresis (CZE) and imaged capillary isoelectric focusing (iCIEF) have been increasingly adopted to assess size heterogeneity, glycosylation heterogeneity and charge heterogeneity in mAbs and related therapeutic modalities. This paper reviews the latest application developments of CE based methods for routine release testing, stability testing and in-depth characterization. In addition, advantages and disadvantages of each of these techniques are critically discussed.

chemistry, analytical
Characterization of the alternative sigma factor sigmaG in Streptomyces coelicolor A3(2).

B. Ševčíková,V. Mazurakova,J. Kormanec

Abstract:Using the previously established two-plasmid system for the identification of promoters recognized by a particular sigma factor, we identified two positive DNA fragments that were active only after induced sigG, encoding sigma factor sigmaG of Streptomyces coelicolor A3(2). High-resolution S1-nuclease mapping in the Escherichia coli two-plasmid system identified potential promoters, PG45 and PG54, whose sequences were similar to the consensus sequence of Bacillus subtilis promoters recognized by the general stress-response sigma factor sigmaB. However, both putative sigmaG-dependent promoters were not active in S. coelicolor. Sequence analysis of the regions potentially governed by the promoters revealed a gene encoding a hypothetical protein SCO5555 and the rrnE gene encoding rRNA operon. To confirm that sigG encodes sigma factor, the sigmaG protein was overproduced in E. coli and purified. In an in vitro transcription assay, sigmaG, after complementation with S. coelicolor core RNA polymerase, was able to recognize both sigmaG-dependent promoters and initiate transcription.
Characterization and elimination of artificial non-covalent light Chain dimers in reduced CE-SDS analysis of pertuzumab

Lei Zhang,Mengdan Fei,Yanqing Tian,Sipeng Li,Xiaoqi Zhu,Linlin Wang,Yanpeng Xu,Michael Hongwei Xie

DOI: https://doi.org/10.1016/j.jpba.2020.113527

2020-10-25

Abstract:Capillary electrophoresis sodium dodecyl sulfate (CE-SDS), either in reduced (rCE-SDS) or non-reduced (nrCE-SDS) form, is widely used for purity evaluation and impurity analysis of monoclonal antibody (mAb) drugs. The accuracy of the method may be interfered by artificial species resulted from sample preparation or electrophoresis operation if it is not well optimized. In a routine analysis of pertuzumab for both innovator Perjeta® and biosimilar HLX11 samples, a cluster of unknown peaks located between light chain (LC) and heavy chain (HC) were observed in rCE-SDS and making the purity of (LC + HC)% unacceptable. They can hardly be reduced by regular method optimization such as changing buffer pH, denaturing temperature or incubation time to achieve the (LC + HC)% expectation. Here, the peaks are first characterized and determined to be non-covalently formed LC-LC dimers by multiple techniques including reversed-phase liquid chromatography-mass spectrometry (LC-MS). These artifacts are then eliminated through enhancing capillary separation temperature to 60 °C and decreasing the separation voltage to 9.5 kV, an unusual CE-SDS operation setting. Finally, a developed rCE-SDS method is presented for successful evaluation of pertuzumab purity and impurities, which is further confirmed by an alternative reduced microchip-based gel electrophoresis. In summary, the developed method provided an accurate and reliable purity evaluation and size variant profiling for batch releasing, stability testing and quality study of reduced pertuzumab samples.
Provably Secure NTRU Instances over Prime Cyclotomic Rings

Yang Yu,Guangwu Xu,Xiaoyun Wang

DOI: https://doi.org/10.1007/978-3-662-54365-8_17

2017-03-28

Abstract:
Analytical Procedure Development and Proposed Established Conditions: A Case Study of a Mass Spectrometry Based NDSRI Analytical Procedure

Jinhui Zhang,Ramesh Raghavachari,Douglas C Kirkpatrick,David A Keire,Xiaoming Xu,Patrick J Faustino

DOI: https://doi.org/10.1016/j.xphs.2024.07.022

Abstract:With the finalization of the ICH Q14 Analytical Procedure Development guideline, how to apply enhanced approaches (such as analytical quality by design (AQbD)) to develop an analytical procedure, and to propose Established Conditions (ECs) and corresponding reporting categories, is increasingly being discussed. To gain practical experience in applying an enhanced approach for method development and identifying ECs, we developed, validated, and implemented an analytical procedure for a nitrosamine drug substance-related impurity (NDSRI). Here, as an example of the application of Q12 Lifecycle Management guideline principles in regards to analytical procedures, we briefly elaborate how: 1) the principles documented in the ICH Q14 guideline for analytical procedure development were applied, with the focus on identifying an Analytical Target Profile (ATP), knowledge management and risk assessment; 2) analytical procedure robustness according to the recommendations in ICH Q2(R2) Validation of Analytical Procedure guideline and Q14, were evaluated; and 3) mass spectrometry ECs and associated proposed reporting categories were proposed.
Increasing Analytical Quality by Designing a Thin-Layer Chromatography Scanner Method for the Determination of the Radiochemical Purity of Radiopharmaceutical Sodium Iodide 131I Oral Solution

Miguel Vasquez-Huaman,Américo Castro-Luna,Norma Julia Ramos-Cevallos,Donald Ramos-Perfecto,Mario Alcarraz-Curi,Jacqueline Segura-Vasquez,Danny Cáceres-Antaurco

DOI: https://doi.org/10.3390/molecules29081883

IF: 4.6

2024-04-21

Molecules

Abstract:The goal of this study was to apply the principles of analytical quality by design (AQbD) to the analytical method for determining the radiochemical purity (PQR) of the radiopharmaceutical sodium iodide 131I oral solution, utilizing thin-layer chromatography (TLC) with a radio–TLC scanner, which also enables the evaluation of product quality. For AQbD, the analytical target profile (ATP), critical quality attributes (CQA), risk management, and the method operable design region (MODR) were defined through response surface methodology to optimize the method using MINITAB® 19 software. This study encompassed the establishment of a control strategy and the validation of the method, including the assessment of selectivity, linearity, precision, robustness, detection limit, quantification limit, range, and the stability of the sample solution. Under the experimental conditions, the method parameters of the TLC scanner were experimentally demonstrated and optimized with an injection volume of 3 μL, a radioactive concentration of 10 mCi/mL, and a carrier volume of 40 μL. Statistical analysis confirmed the method's selectivity for the 131I iodide band Rf of 0.8, a radiochemical impurity IO3− Rf of 0.6, a linearity from 6.0 to 22.0 mCi/mL, and an intermediate precision with a global relative standard deviation (RSD) of 0.624%. The method also exhibited robustness, with a global RSD of 0.101%, a detection limit of 0.09 mCi/mL, and a quantification limit of 0.53 Ci/mL, meeting the prescribed range and displaying stability over time (at 0, 2, and 20 h) with a global RSD of 0.362%, resulting in consistent outcomes. The development of a method based on AQbD facilitated the creation of a design space and an operational space, with comprehensive knowledge of the method's characteristics and limitations. Additionally, throughout all operations, compliance with the acceptance criteria was verified. The method's validity was confirmed under the established conditions, making it suitable for use in the manufacturing process of sodium iodide 131I and application in nuclear medicine services.

chemistry, multidisciplinary,biochemistry & molecular biology
Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells*

K. Hisaoka-Nakashima,Kanako Miyano,Chie Matsumoto,N. Kajitani,Hiromi Abe,Mami Okada-Tsuchioka,Akinobu Yokoyama,Y. Uezono,N. Morioka,Y. Nakata,M. Takebayashi

DOI: https://doi.org/10.1074/jbc.M114.622415

IF: 5.485

2015-04-13

Journal of Biological Chemistry

Abstract:Background: A significant non-neural, monoamine-independent mechanism underlies the antidepressant effect of amitriptyline. Results: Amitriptyline-evoked GDNF production is mediated by pertussis toxin (PTX)-sensitive Gαi/o. Conclusion: PTX-sensitive Gαi/o activation is critical for the cascade that underpins the biological effect of amitriptyline. Significance: Further elaboration of the intracellular mechanism of amitriptyline could lead to greater understanding of depression and novel antidepressant treatments. Further elaborating the mechanism of antidepressants, beyond modulation of monoaminergic neurotransmission, this study sought to elucidate the mechanism of amitriptyline-induced production of glial cell line-derived neurotrophic factor (GDNF) in astroglial cells. Previous studies demonstrated that an amitriptyline-evoked matrix metalloproteinase (MMP)/FGF receptor (FGFR)/FGFR substrate 2α (FRS2α)/ERK cascade is crucial for GDNF production, but how amitriptyline triggers this cascade remains unknown. MMP is activated by intracellular mediators such as G proteins, and this study sought to clarify the involvement of G protein signaling in amitriptyline-evoked GDNF production in rat C6 astroglial cells (C6 cells), primary cultured rat astrocytes, and normal human astrocytes. Amitriptyline-evoked GDNF mRNA expression and release were inhibited by pertussis toxin (PTX), a Gαi/o inhibitor, but not by NF449, a Gαs inhibitor, or YM-254890, a Gαq inhibitor. The activation of the GDNF production cascade (FGFR/FRS2α/ERK) was also inhibited by PTX. Deletion of Gαο1 and Gαi3 by RNAi demonstrated that these G proteins play important roles in amitriptyline signaling. G protein activation was directly analyzed by electrical impedance-based biosensors (CellKeyTM assay), using a label-free (without use of fluorescent proteins/probes or radioisotopes) and real time approach. Amitriptyline increased impedance, indicating Gαi/o activation that was suppressed by PTX treatment. The impedance evoked by amitriptyline was not affected by inhibitors of the GDNF production cascade. Furthermore, FGF2 treatment did not elicit any effect on impedance, indicating that amitriptyline targets PTX-sensitive Gαi/o upstream of the MMP/FGFR/FRS2α/ERK cascade. These results suggest novel targeting for the development of antidepressants.

A comparison of point and ball iterations in the contractive mapping case

Analysis and Optimal Design of Batch and Two‐column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

Analysis and Optimal Design of Batch and Two-Column Continuous Chromatographic Frontal Processes for Monoclonal Antibody Purification

68Ga-labeled macroaggregates for lung studies.

A case study application of AQbD to the re-development and validation of an affinity chromatography analytical procedure for mAb titer quantitation

[To further improve the techniques for repair and reconstruction of skin and soft tissue defects around the knee joints].

Establishment and validation of a microfluidic capillary gel electrophoresis platform method for purity analysis of therapeutic monoclonal antibodies

Quality by Design Study of the Direct Analysis in Real Time Mass Spectrometry Response

Accelerated development of a SEC-HPLC procedure for purity analysis of monoclonal antibodies using design of experiments

Seizures at the scale of individual neurons.

Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring

Determination of size variants by CE-SDS for approved therapeutic antibodies: Key implications of subclasses and light chain specificities

Delivery of primary care services among family planning centers: a response to managed care?

Improved CE(SDS)-CZE-MS method utilizing an 8-port nanoliter valve

Capillary electrophoresis and the biopharmaceutical industry: Therapeutic protein analysis and characterization

Characterization of the alternative sigma factor sigmaG in Streptomyces coelicolor A3(2).

Characterization and elimination of artificial non-covalent light Chain dimers in reduced CE-SDS analysis of pertuzumab

Provably Secure NTRU Instances over Prime Cyclotomic Rings

Analytical Procedure Development and Proposed Established Conditions: A Case Study of a Mass Spectrometry Based NDSRI Analytical Procedure

Increasing Analytical Quality by Designing a Thin-Layer Chromatography Scanner Method for the Determination of the Radiochemical Purity of Radiopharmaceutical Sodium Iodide 131I Oral Solution

Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells*